Ascelia Pharma - Just about to submit Orviglance for US approval

Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early September. The second critical value driver is to secure a US partner for the upcoming launch.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/